Ixekizumab对比依那西普和安慰剂治疗中重度斑块状银屑病伴非脓疱性掌跖受累的疗效:三项3期试验结果
该分析基于UNCOVER-1、2、3三项3期双盲安慰剂对照试验,评估Ixekizumab在中重度斑块状银屑病伴中重度非脓疱性掌跖受累患者中的疗效。结果显示,第12周时Ixekizumab组达到PPASI 50、75、100的比例均显著高于安慰剂和依那西普,且起效早至第1周,持续治疗至第60周疗效维持或改善。
要点
- Ixekizumab在掌跖受累患者中第12周PPASI 50/75/100应答显著优于安慰剂和依那西普。
- Ixekizumab与对照组的疗效差异最早在第1周即出现统计学显著性。
- 继续Ixekizumab Q4W治疗至第60周,疗效维持或进一步改善。
核心结论
- 在中重度非脓疱性掌跖受累且中重度斑块状银屑病患者中,Ixekizumab第12周疗效优于安慰剂和依那西普,且起效更快,持续治疗可维持改善。
研究设计与样本
- 三项3期双盲安慰剂对照试验(UNCOVER-1 N=1296;UNCOVER-2 N=1224;UNCOVER-3 N=1346)的亚组分析。
- 患者随机接受皮下Ixekizumab 80mg每2周或每4周(起始160mg)或安慰剂至第12周;UNCOVER-2和3另设依那西普50mg每2周组。
- UNCOVER-3开放扩展期患者第12-60周接受Ixekizumab每4周治疗。
- 中重度掌跖受累定义为掌跖银屑病面积和严重度指数(PPASI)≥8。
主要发现
- 第12周达到PPASI 50的比例:Ixekizumab约80%,安慰剂32.9%,依那西普67.8%(所有P<0.05)。
- 第12周达到PPASI 75的比例:Ixekizumab约70%,安慰剂18.8%,依那西普44.1%(所有P<0.05)。
- 第12周达到PPASI 100的比例:Ixekizumab约50% vs 安慰剂8.2%(P<0.001);Ixekizumab每2周组51.8% vs 依那西普32.2%(P<0.05)。
- 继续Ixekizumab每4周治疗至第60周,疗效维持或改善;与安慰剂或依那西普的差异最早在第1周即达统计学显著。
关键数值与推荐
- 中重度掌跖受累定义:PPASI≥8。
- 第12周PPASI 50应答率:Ixekizumab约80%,安慰剂32.9%,依那西普67.8%(P<0.05)。
- 第12周PPASI 75应答率:Ixekizumab约70%,安慰剂18.8%,依那西普44.1%(P<0.05)。
- 第12周PPASI 100应答率:Ixekizumab约50% vs 安慰剂8.2%(P<0.001);Ixekizumab每2周51.8% vs 依那西普32.2%(P<0.05)。
临床怎么用
- 对于中重度斑块状银屑病合并中重度非脓疱性掌跖受累患者,Ixekizumab可作为优于依那西普和安慰剂的治疗选择。
- Ixekizumab起效迅速,第1周即显现疗效差异,适合需要快速控制掌跖症状的患者。
- 长期维持治疗至第60周可保持或进一步提升掌跖疗效。
局限性
- 此为3期试验的亚组分析,非预设主要终点。
- 掌跖受累亚组样本量相对较小(中重度n=350)。
- 开放扩展期无对照,长期数据需谨慎解读。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Palmoplantar psoriasis has significant physical and emotional impact on patients and can be difficult to treat. OBJECTIVE: To evaluate the efficacy of ixekizumab in the treatment of patients with moderate-to-severe plaque psoriasis and moderate-to-severe non-pustular palmoplantar involvement. METHODS: In three phase 3, double-blind, placebo-controlled trials, patients with moderate-to-severe non-pustular plaque psoriasis [UNCOVER-1 (N = 1296), UNCOVER-2 (N = 1224), UNCOVER-3 (N = 1346)] were randomized to subcutaneous 80 mg ixekizumab every 2 or 4 weeks (Q2W, Q4W), after a 160-mg starting dose, or placebo through week 12. Additional UNCOVER-2 and UNCOVER-3 cohorts were randomized to 50 mg etanercept biweekly. Patients entering the open-label long-term extension (UNCOVER-3) received ixekizumab Q4W weeks 12-60. Moderate-to-severe palmoplantar involvement was defined as Palmoplantar Psoriasis Area and Severity Index (PPASI) ≥8. RESULTS: Twenty-eight percent of UNCOVER-1, UNCOVER-2 and UNCOVER-3 patients had baseline palmoplantar involvement (PPASI ≥0, n = 1092) and 9.1% (n = 350) had moderate-to-severe involvement, with mean baseline PPASI ~20, PASI ~24, and most (>60%) had static Physician's Global Assessment ≥4. Higher percentages of patients treated with ixekizumab vs. placebo or etanercept achieved PPASI 50 (approximately 80% vs. 32.9%, 67.8%; ixekizumab, placebo, etanercept, respectively) and PPASI 75 (approximately 70% vs. 18.8%, 44.1%; ixekizumab, placebo, etanercept, respectively) at week 12 (all P < 0.05). PPASI 100 was achieved by higher percentages of ixekizumab-treated patients vs. placebo (approximately 50% vs. 8.2%, P < 0.001) and ixekizumab Q2W-treated patients vs. etanercept (51.8% vs. 32.2%, P < 0.05). Outcomes were maintained or improved in patients continuing on ixekizumab Q4W through week 60. Differences between ixekizumab and placebo or etanercept were statistically significant as early as week 1. CONCLUSION: In a subpopulation analysis of patients from phase 3 trials with moderate-to-severe non-pustular palmoplantar involvement and moderate-to-severe plaque psoriasis, ixekizumab treatment resulted in greater and more rapid improvements than placebo and etanercept at week 12; improvements were sustained with continued treatment.
引用
- Menter A, Warren RB, Langley RG, et al. Efficacy of ixekizumab compared to etanercept and placebo in patients with moderate-to-severe plaque psoriasis and non-pustular palmoplantar involvement: results from three phase 3 trials (UNCOVER-1, UNCOVER-2 and UNCOVER-3). J Eur Acad Dermatol Venereol. 2017. PMID: 28322474. doi:10.1111/jdv.14237
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。